Caplin Point Laboratories Ltd

Caplin Point Lab Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Caplin Point Laboratories Ltd

₹ 2,153 -0.46%
30 May - close price
caplinpoint.net BSE: 524742 NSE: CAPLIPOINT
About

Caplin Point Laboratories Ltd is engaged in the manufacturing and sourcing of APIs, finished formulations, R&D, clinical research with presence in Latin America, Africa, USA and other nations.[1]

Key Points

Product Portfolio
The company offers a range of pharmaceutical products, with 4,000+ registered licenses and 650 formulations across 36 therapeutic areas. Its product line includes more than 65% of the drugs on the WHO essential drug list. The portfolio features various forms like tablets, capsules, injections, eye drops, oral liquids, soft gel capsules, ointments, creams, gels, injectable powders, suppositories, ovules, pre-mix bag formulations, inhalers, sprays, and IV infusions. [1] [2]

Website BSE NSE
  • Market Cap ₹ 16,362 Cr.
  • Current Price ₹ 2,153
  • High / Low ₹ 2,641 / 1,221
  • Stock P/E 48.2
  • Book Value ₹ 224
  • Dividend Yield 0.23 %
  • ROCE 28.6 %
  • ROE 22.0 %
  • Face Value ₹ 2.00
Edit ratios

Pros

  • Company is almost debt free.

Cons

  • Stock is trading at 9.62 times its book value
  • The company has delivered a poor sales growth of 7.35% over past five years.
  • Earnings include an other income of Rs.135 Cr.
  • Working capital days have increased from 116 days to 248 days

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals

Part of BSE 500 BSE Healthcare Nifty 500 BSE SmallCap BSE Allcap

Edit Columns
Loading peers table ...

Quarterly Results

Standalone Figures in Rs. Crores / View Consolidated

Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025
112 116 137 131 145 174 179 133 139 186 208 185 174
74 70 80 79 80 97 90 70 82 104 110 108 99
Operating Profit 38 46 57 52 65 77 89 63 58 81 98 77 75
OPM % 34% 40% 42% 39% 45% 44% 50% 48% 41% 44% 47% 42% 43%
10 35 22 29 12 27 24 18 36 22 43 29 41
Interest 0 0 0 0 0 0 0 0 0 0 0 0 0
Depreciation 7 6 7 6 6 7 7 7 7 6 6 6 6
Profit before tax 42 75 73 74 71 97 107 74 87 97 135 100 110
Tax % 30% 15% 22% 20% 23% 22% 23% 26% 20% 25% 21% 25% 21%
29 63 58 59 54 76 82 55 70 73 106 75 86
EPS in Rs 3.83 8.34 7.59 7.80 7.16 10.04 10.81 7.30 9.20 9.54 13.91 9.83 11.38
Raw PDF

Profit & Loss

Standalone Figures in Rs. Crores / View Consolidated

Jun 2014 Jun 2015 Mar 2016 9m Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
166 240 231 342 427 537 528 483 528 529 625 752
132 183 169 248 284 348 321 269 308 308 337 420
Operating Profit 34 57 63 94 142 189 207 214 220 220 288 332
OPM % 20% 24% 27% 27% 33% 35% 39% 44% 42% 42% 46% 44%
3 3 3 13 23 35 66 19 56 99 105 135
Interest 1 1 0 0 1 0 0 0 0 0 0 0
Depreciation 3 8 7 13 19 21 20 22 26 26 27 25
Profit before tax 33 51 58 93 146 203 253 210 250 293 366 442
Tax % 23% 19% 22% 24% 30% 27% 22% 26% 25% 20% 22% 23%
26 41 45 70 102 148 198 156 188 234 284 339
EPS in Rs 3.39 5.42 6.00 9.30 13.53 19.59 26.13 20.65 24.79 30.86 37.36 44.66
Dividend Payout % 24% 18% 20% 16% 15% 11% 10% 15% 16% 15% 13% 12%
Compounded Sales Growth
10 Years: 16%
5 Years: 7%
3 Years: 13%
TTM: 20%
Compounded Profit Growth
10 Years: 29%
5 Years: 12%
3 Years: 22%
TTM: 20%
Stock Price CAGR
10 Years: 29%
5 Years: 45%
3 Years: 42%
1 Year: 67%
Return on Equity
10 Years: 26%
5 Years: 22%
3 Years: 22%
Last Year: 22%

Balance Sheet

Standalone Figures in Rs. Crores / View Consolidated

Jun 2014 Jun 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Equity Capital 15 15 15 15 15 15 15 15 15 15 15 15
Reserves 47 79 113 185 280 417 585 744 915 1,125 1,375 1,686
3 2 2 1 1 1 2 1 1 1 1 2
109 128 132 116 115 107 89 101 123 162 131 112
Total Liabilities 174 223 263 317 411 539 691 861 1,054 1,303 1,522 1,814
101 111 143 152 169 138 167 183 162 157 166 205
CWIP 25 31 0 3 15 9 4 1 3 43 28 21
Investments 1 1 1 19 48 168 196 149 265 485 584 802
48 80 118 143 178 225 325 528 624 618 745 786
Total Assets 174 223 263 317 411 539 691 861 1,054 1,303 1,522 1,814

Cash Flows

Standalone Figures in Rs. Crores / View Consolidated

Jun 2014 Jun 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
60 50 44 55 23 107 87 295 231 157 111 196
-44 -24 -6 -37 -60 -76 -41 -4 -276 -86 -118 -140
-6 -9 -14 -7 -12 -15 -33 -3 -23 -30 -34 -38
Net Cash Flow 10 17 24 12 -49 16 13 287 -68 41 -41 18

Ratios

Standalone Figures in Rs. Crores / View Consolidated

Jun 2014 Jun 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Debtor Days 0 0 11 3 74 85 151 74 37 61 75 85
Inventory Days 29 36 56 50 58 36 34 47 76 95 153 102
Days Payable 100 108 161 149 148 92 79 131 116 130 140 93
Cash Conversion Cycle -72 -72 -94 -95 -16 30 107 -10 -2 26 89 93
Working Capital Days -175 -125 -112 -44 44 62 137 61 96 24 76 248
ROCE % 60% 64% 60% 56% 58% 55% 48% 30% 29% 28% 29% 29%

Shareholding Pattern

Numbers in percentages

Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025
68.88% 68.88% 68.80% 70.66% 70.63% 70.62% 70.62% 70.62% 70.56% 70.56% 70.56% 70.56%
2.03% 2.15% 2.24% 2.36% 2.68% 3.09% 2.84% 3.33% 3.38% 3.71% 4.86% 5.73%
1.12% 1.12% 1.12% 0.64% 0.27% 0.21% 0.43% 1.08% 1.49% 1.83% 2.11% 2.00%
27.97% 27.85% 27.84% 26.33% 26.44% 26.08% 26.11% 24.95% 24.59% 23.93% 22.48% 21.72%
No. of Shareholders 84,86884,53882,68782,14678,95678,06879,43881,40980,41196,12392,70296,387

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

Concalls